Eptifibatide
Eptifibatide is an injectable medication that prevents blood clots by inhibiting platelet aggregation. It's administered intravenously and used to treat acute coronary syndromes, reducing the risk of heart attacks. Available in strengths like 2 mg/mL and 75 mg/100 mL from Slate Run Pharmaceuticals. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Eptifibatide is an injectable medication that prevents blood clots by inhibiting platelet aggregation. It's administered intravenously and used to treat acute coronary syndromes, reducing the risk of heart attacks. Available in strengths like 2 mg/mL and 75 mg/100 mL from Slate Run Pharmaceuticals. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Eptifibatide",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Eptifibatide — ANDA 204693 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204693"
}
]
|
| identifier | ANDA204693 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"fda",
"health-care",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Eptifibatide |
